AM, Musen G, Ryan CM, et al.: Longterm effect of diabetes and its treatment on cognitive function. N Engl J Med 2007, 356:1842-1852. Rating: •Of importance.Introduction: One important concern for patients with type 1 diabetes and clinicians is the immediate and longterm impact of diabetes and its treatment on cognitive function. The DCCT (Diabetes Control and Complications Trial) sought to determine the relative benefits and risks of intensive treatment of type 1 diabetes, and particularly to address the question of whether intensive treatment that targeted glucose levels in the near-normal range led to better outcomes, including less microvascular complications, than the less rigorous conventional treatment of type 1 diabetes [1]. Results showed that intensive treatment delayed the onset and slowed the progression of microvascular complications, but at the expense of a threefold increase in hypoglycemia. This increased frequency of severe hypoglycemia has proven to be an important treatment-limiting factor. As part of the effort to establish the safety of intensive treatment, the DCCT investigators measured neurocognitive function at baseline and at several time points throughout the study, including study end.Although the acute disruptive effects of severe hypoglycemia on cognition are well known [2], the long-term effects remain in question. Several earlier studies have suggested that severe hypoglycemia, over time, is associated with cognitive decline in people with type 1 diabetes [3,4]. When the DCCT reported that recurrent severe hypoglycemia did not permanently impact cognitive function over time [5] (data consistent with those of a smaller study previously published [6]), the report was met with some skepticism [7]. Although a re-analysis of the DCCT data demonstrated the relative safety of intensive treatment in terms of cognition over the average 6.5 years of the study participation [8], the question of the longer-term impact remained. The EDIC (Epidemiology of Diabetes Interventions and Complications) was established to continue to follow the well-characterized patients studied in the DCCT to obtain an important longitudinal perspective on the health impact of type 1 diabetes, for an average of 18 years of follow-up from the beginning of the DCCT. A separately funded study during year 12 of the EDIC examined the long-term neurocognitive effects of diabe-